Clinical trials: Systemic Disease
Systemic Lupus Erythematosus
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)
- Trial name
- EMBODY1 (NCT01262365)
- Testing
- Epratuzumab
- Where
- 141 sites in United States, Australia and 19 more
- Volunteers
- 793 people
- Sponsor
- UCB Pharma
Prostate Cancer
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
Determine the effect of enzalutamide and dutasteride or finasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.
- Trial name
- NCT02213107
- Testing
- Enzalutamide and Dutasteride or finasteride
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Rochester
Follicular Lymphoma, Marginal Zone Lymphoma
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT01239394
- Testing
- ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
The hypothesis: Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
- Trial name
- REDUCED (NCT01031095)
- Testing
- coronary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Bursa Postgraduate Hospital
Ovarian Cancer, Fallopian Tubes Cancer
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic…
- Conditions
- Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
- Trial name
- NCT01767675
- Testing
- Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified.
- Conditions
- Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism
- Trial name
- NCT02889562
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sanford Health
Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic…
- Trial name
- NCT02939014
- Testing
- Brentuximab Vedotin
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Takeda
Psoriasis
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- NCT04908475
- Testing
- Risankizumab, Apremilast
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 352 people
- Sponsor
- AbbVie
Hypovitaminosis D
Cholecalciferol Supplementation for Sepsis in the ICU
Sepsis in a clinical entity that occurs in patients with serious infections. Though the severity of illness may vary, every year, approximately 1.6 million Americans are treated for sepsis.
- Trial name
- CSI (NCT01896544)
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
Scleroderma
Taking Charge of Systemic Sclerosis
This Study is a collaborative project with partners (people with scleroderma and stakeholders) designed to refine an internet program for patients with scleroderma and to compare the internet program to an authoritative…
- Trial name
- TOSS (NCT02494401)
- Testing
- Internet-based self-management program, Scleroderma book
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- University of Michigan
Multiple Myeloma
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
Eligible patients have multiple myeloma with measurable disease in the blood and a targetable soft tissue or bony lesion with radiotherapy.
- Trial name
- RISE-M (NCT03634800)
- Testing
- Nivolumab 240mg, Radiation therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Lupus Erythematosus, Lupus Nephritis
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
- Trial name
- EQUALISE (NCT04128579)
- Testing
- Itolizumab [Bmab 600]
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 52 people
- Sponsor
- Biocon Limited
Dexamethasone, Glucocorticoids
High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy
The aim of this study is to investigate the effect of a single preoperative high-dose steroid injection on complications in the immediate postoperative phase after breast cancer surgery, with removal of the breast (mastectomy).
- Conditions
- Dexamethasone, Glucocorticoids, Mastectomy, Breast Cancer
- Trial name
- DEX-MAS (NCT03125941)
- Testing
- Dexamethasone
- Where
- Denmark
- Volunteers
- 130 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine…
- Trial name
- NCT05104866
- Testing
- Dato-DXd, Capecitabine, Gemcitabine
- Where
- 167 sites in United States, Argentina and 18 more
- Volunteers
- 732 people
- Sponsor
- AstraZeneca
Systemic Sclerosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis.
- Trial name
- NOVESA (NCT03798366)
- Testing
- GLPG1690
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Sepsis, Necrotising Enterocolitis Neonatal
Integrated Predictive Monitoring for Sepsis and Necrotizing Enterocolitis
Behind the scenes pilot trial in the computer lab involving chart review to use neonatal intensive care unit data to create computer models predicting sepsis and necrotizing enterocolitis in very small premature infants
- Trial name
- PREMO (K) (NCT07254559)
- Testing
- No Intervention: Observational Cohort
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Virginia
Systemic Lupus Erythematosus
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
- Trial name
- NCT03845517
- Testing
- PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Pfizer
Lupus Erythematosus, Systemic
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks.
- Trial name
- NCT02041091
- Testing
- Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
- Where
- 44 sites in United States, Puerto Rico and 1 more
- Volunteers
- 226 people
- Sponsor
- Eli Lilly and Company